一追再追
08-11
$INNOVENT BIO(01801)$ 

摩根大通最新研報力挺信達生物(01801),將目標價上調至109港元,予“增持”評級,列為行業首選!研報指出,對外授權成為內地生物醫藥核心驅動力,信達憑藉強大產品管線,覆蓋腫瘤、心血管、自身免疫及眼科等領域,多元化資產組合蓄勢待發,未來數年有望持續達成授權交易。摩根大通上調潛在授權收入佔比預測至5%-7%,並預期毛利率因銷售結構優化而擴張。信達研發能力獲市場高度認可,早期資產估值激增43%。憑藉領先的創新能力和多元化戰略,信達生物投資價值凸顯!

01801
08-11 10:13
HKINNOVENT BIO
SidePrice | FilledRealized P&L
Buy
Open
86.25
500
--
Closed
INNOVENT BIO
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Trade Feed Decoder
    08-11
    Trade Feed Decoder
    当前评论仅支持在app查看。
  • snappyz
    08-13
    snappyz
    Wow, such a bullish outlook on INNOVENT BIO! [Wow]
Leave a comment
2
16